SCHEMBL2771887

SCHEMBL2771887

CCOC(=O)Cc1c(C)c(Sc2ccc(S(=O)(=O)N3CCOCC3)cc2)n2cc(F)ccc12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.47
ALDH1A1 P00352 5/20 0.46
MAPK1 P28482 2/20 0.46
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
KMT2A Q03164 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
HSD17B10 Q99714 3/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
USP2 O75604 2/20 0.41
PKM P14618 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
CREBBP Q92793 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2769602 0.90 PTGDR2 (0.58) PTGDR2LMNAPKMGAA
SCHEMBL3300027 0.89 PTGDR2 (0.61) PTGDR2ALDH1A1MAPK1LMNATSHR
SCHEMBL3564465 0.86 PTGDR2 (0.52) PTGDR2ALDH1A1LMNATSHRKMT2A
SCHEMBL2771395 0.84 ALDH1A1 (0.44) ALDH1A1MAPK1LMNATSHRKMT2A
SCHEMBL2774269 0.84 PTGDR2 (0.51) PTGDR2ALDH1A1LMNATSHRKMT2A
SCHEMBL3579992 0.83 PTGDR2 (0.48) PTGDR2ALDH1A1LMNATSHRKMT2A
SCHEMBL3304453 0.81 PTGDR2 (0.46) PTGDR2ALDH1A1MAPK1LMNAKMT2A
SCHEMBL3569716 0.80 PTGDR2 (0.45) PTGDR2ALDH1A1LMNATSHRKMT2A
SCHEMBL2771246 0.80 PTGDR2 (0.46) PTGDR2ALDH1A1LMNATSHRKMT2A
SCHEMBL3303151 0.79 CYP2C9 (0.44) PTGDR2ALDH1A1MAPK1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910357-B1 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LTD (GB) 2010-04-14 EP disclosed
US-20090163534-A1 Indolizine Derivatives ARGENTA DISCOVERY LIMITED (GB) 2009-06-25 US disclosed
EP-1910357-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS Argenta Discovery Limited (GB) 2008-04-16 EP disclosed
WO-2006136859-A2 INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163534-A1 Indolizine Derivatives HRH4, HRH2, NR1H2 PTGDR2 363/4885ALDH1A1 3086/4885MAPK1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.